


CLAIMS

What is claimed is:

1. A method of lowering body temperature of an individual, comprising administering to the individual an effective amount of at least one compound according to Formula I:



wherein:

R^1 is $-(C_1-C_7)$ hydrocarbyl or $-(C_2-C_6)$ heteroalkyl;

R^2 is selected from the group consisting of $-H$, and $-(C_1-C_7)$ hydrocarbyl;

wherein R^1 and R^2 may combine to form a carbocyclic or heterocyclic 5- or 6-membered ring;

R^{3a} , R^{3b} and R^{3c} are independently selected from the group consisting of $-H$, $-O(C_1-C_7)$ hydrocarbyl, $-OH$, $-OC(=O)(C_1-C_6)$ alkyl, $-OC(=O)O(C_1-C_7)$ hydrocarbyl, $-SH$, $-S(C_1-C_3)$ alkyl, $-NH_2$, $-NH(C_1-C_6)$ alkyl, $-N((C_1-C_6)alkyl)_2$, $-NH(=O)(C_1-C_6)$ alkyl, $-NO_2$, and halogen;

provided at least one of R^{3a} , R^{3b} and R^{3c} is other than $-H$;


R^4 and R^5 are independently selected from the group consisting of $-O(C_1-C_7)$ hydrocarbyl, $-OH$, $-OC(=O)(C_1-C_6)$ alkyl, $-OC(=O)O(C_1-C_7)$ hydrocarbyl, $-SH$, $-S(C_1-C_3)$ alkyl, $-NH_2$, $-NH(C_1-C_6)$ alkyl, $-N((C_1-C_6)alkyl)_2$, $-NH(=O)(C_1-C_6)$ alkyl, $-NO_2$, and halogen;

wherein R^4 and R^5 may combine to form a 5-, 6- or 7-membered heterocyclic ring; and

wherein the administered compounds according to Formula I comprise an (*S*)-enantiomer, substantially free of the corresponding (*R*)-enantiomer, with respect to the absolute conformation at the 5-position of the benzodiazepine ring; or

a pharmaceutically-acceptable salt of such a compound.

2. The method according to claim 1 wherein the administered compound is a compound according to Formula II:



wherein:

R^1 is $-(C_1-C_7)$ hydrocarbyl or $-(C_2-C_6)$ heteroalkyl;

R^2 is selected from the group consisting of $-H$, and $-(C_1-C_7)$ hydrocarbyl;

wherein R^1 and R^2 may combine to form a carbocyclic or heterocyclic 5- or 6-membered ring;

R^{3a} , R^{3b} and R^{3c} are independently selected from the group consisting of $-H$, $-O(C_1-C_7)$ hydrocarbyl, $-OH$, $-OC(=O)(C_1-C_6)$ alkyl, $-OC(=O)O(C_1-C_7)$ hydrocarbyl, $-SH$, $-S(C_1-C_3)$ alkyl, $-NH_2$, $-NH(C_1-C_6)$ alkyl, $-N((C_1-C_6)alkyl)_2$, $-NH(=O)(C_1-C_6)$ alkyl, $-NO_2$, and halogen;

provided that at least one of R^{3a} and R^{3b} is other than $-H$;

R^4 and R^5 are independently selected from the group consisting of $-O(C_1-C_7)$ hydrocarbyl, $-OH$, $-OC(=O)(C_1-C_6)$ alkyl, $-OC(=O)O(C_1-$

C₇)hydrocarbyl, -SH, -S(C₁-C₃)alkyl, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-C₆)alkyl)₂, -NH(=O)(C₁-C₆)alkyl, -NO₂, and halogen;

wherein R⁴ and R⁵ may combine to form a 5-, 6- or 7-membered heterocyclic ring; and

wherein the administered compounds according to Formula I comprise an (*S*)-enantiomer, substantially free of the corresponding (*R*)-enantiomer, with respect to the absolute conformation at the 5-position of the benzodiazepine ring; or

a pharmaceutically-acceptable salt of such a compound.

3. The method according to claim 2;

wherein:

R^{3c} is -H;

one or two of R^{3a}, R^{3b}, R⁴, and R⁵ is -OH; and

the remaining members of the group R^{3a}, R^{3b}, R⁴, R⁵ are independently selected from the group consisting of -O(C₁-C₇)hydrocarbyl, -OC(=O)(C₁-C₆)alkyl, -OH, -SH, -S(C₁-C₃)alkyl, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-C₆)alkyl)₂, -NH(=O)(C₁-C₆)alkyl, -NO₂, and halogen;

wherein R⁴ and R⁵ may combine to form a 5-, 6- or 7-membered heterocyclic ring.

4. The method according to claim 3,

wherein:

one or two of R^{3a}, R^{3b}, R⁴, and R⁵ is -OH;

one of the remaining members of the group R^{3a}, R^{3b}, R⁴, and R⁵ is -O(C₁-C₇)hydrocarbyl; and

the remaining members of the group R^{3a}, R^{3b}, R⁴, and R⁵ are independently selected from the group consisting of -O(C₁-C₇)hydrocarbyl, -OC(=O)(C₁-C₆)alkyl, -SH, -S(C₁-C₃)alkyl, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-C₆)alkyl)₂, -NH(=O)(C₁-C₆)alkyl, -NO₂ and halogen;

wherein R⁴ and R⁵ may combine to form a 5-, 6- or 7-membered heterocyclic ring.

5. The method according to claim 4,
wherein:
one or two of R^{3a} , R^{3b} , R^4 , and R^5 is $-OH$; and
the remaining members of the group R^{3a} , R^{3b} , R^4 , and R^5 are
independently selected from the group consisting of $-O(C_1-C_7)$ hydrocarbyl.

6. The method according to claim 5,
wherein:
the compound according to Formula II is selected from the group
consisting of:

(*S*)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-hydroxy-8-methoxy-
5H-2,3-benzodiazepine;

(*S*)-1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-
5H-2,3-benzodiazepine;

(*S*)-1-(3-methoxy-4-hydroxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-
5H-2,3-benzodiazepine;

(*S*)-1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-
5H-2,3-benzodiazepine;

(*S*)-1-(3-methoxy-4-hydroxyphenyl)-4-methyl-5-ethyl-7-hydroxy-8-
methoxy-5H-2,3-benzodiazepine;

(*S*)-1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7-hydroxy-8-
methoxy-5H-2,3-benzodiazepine; and

pharmaceutically-acceptable salts of such compounds.

7. The method according to claim 2
wherein:
 R^{3c} is $-H$; and
 R^{3a} , R^{3b} , R^4 , and R^5 are independently selected from the group consisting
of $-O(C_1-C_7)$ hydrocarbyl.

8. A method according to claim 7, wherein the administered
compound is (*S*)-tofisopam, or a pharmaceutically-acceptable salt thereof.

9. The method according to claim 1 wherein said individual is afflicted with a disorder associated with an elevated body temperature.

10. The method according to claim 9 wherein the disorder is fever.

11. The method according to claim 9 wherein the disorder is malignant hyperthermia.

12. The method according to claim 9 wherein the disorder is serotonin syndrome.

13. The method according to claim 9 wherein the disorder comprises hot flashes.

14. The method according to claim 13 wherein said hot flashes occur during menopause.

15. The method according to claim 13 wherein said hot flashes occur during perimenopause.

16. The method of claim 13 wherein said hot flashes are side effects of drug therapy.

17. The method of claim 13 wherein said hot flashes occur subsequent to the removal of estrogen-producing tissue.

18. The method of claim 13 wherein said hot flashes occur subsequent to organ failure of estrogen-producing organs.


19. The method of claim 1 wherein said individual is afflicted with a disorder wherein therapeutic benefit is achieved by lowering of the body temperature to a level below the normal body temperature.

20. The method of claim 19 wherein the disorder is cerebral ischemia.

21. The method of claim 19 wherein the disorder is stroke.

22. A method of lowering body temperature of an individual suffering from hot flashes associated with menopause, comprising administering to said individual an effective amount of

(a) at least one compound according to Formula I:



wherein:

R^1 is $-(C_1-C_7)$ hydrocarbyl or $-(C_2-C_6)$ heteroalkyl;

R^2 is selected from the group consisting of $-H$, and $-(C_1-C_7)$ hydrocarbyl;

wherein R^1 and R^2 may combine to form a carbocyclic or heterocyclic 5- or 6-membered ring;

R^{3a} , R^{3b} and R^{3c} are independently selected from the group consisting of $-H$, $-O(C_1-C_7)$ hydrocarbyl, $-OH$, $-OC(=O)(C_1-C_6)$ alkyl, $-OC(=O)O(C_1-C_7)$ hydrocarbyl, $-SH$, $-S(C_1-C_3)$ alkyl, $-NH_2$, $-NH(C_1-C_6)$ alkyl, $-N((C_1-C_6)alkyl)_2$, $-NH(=O)(C_1-C_6)$ alkyl, $-NO_2$, and halogen;

provided at least one of R^{3a} , R^{3b} and R^{3c} is other than $-H$;

R^4 and R^5 are independently selected from the group consisting of $-O(C_1-C_7)$ hydrocarbyl, $-OH$, $-OC(=O)(C_1-C_6)$ alkyl, $-OC(=O)O(C_1-$

C₇)hydrocarbyl, -SH, -S(C₁-C₃)alkyl, -NH₂, -NH(C₁-C₆)alkyl, -N((C₁-C₆)alkyl)₂, -NH(=O)(C₁-C₆)alkyl, -NO₂, and halogen;

wherein R⁴ and R⁵ may combine to form a 5-, 6- or 7-membered heterocyclic ring; and

wherein the administered compounds according to Formula I comprise an (*S*)-enantiomer, substantially free of the corresponding (*R*)-enantiomer, with respect to the absolute conformation at the 5-position of the benzodiazepine ring; or

a pharmaceutically-acceptable salt of such a compound; and

(b) one or more additional therapeutic agents selected from the group consisting of estrogen agonists, progesterone agonists, selective estrogen receptor modulators, bisphosphonates, selective serotonin reuptake inhibitors, norepinephrine serotonin reuptake inhibitors and gamma aminobutyric acid modulators.

23. The method according to claim 22, wherein the one or more additional therapeutic agents comprises an estrogen agonist and a progesterone agonist.

24. The method according to claim 22 or claim 23, wherein the estrogen agonist is estradiol.

25. The method according to claim 22 or 23, wherein the progesterone agonist is trimegestrone.

26. The method according to claim 22, wherein the selective estrogen receptor modulator agonist is selected from the group consisting of raloxifene and bazedoxifene.


27. The method according to claim 22, wherein the bisphosphonate is selected from the group consisting of risedronic acid and ibandronic.

28. The method according to claim 22, wherein the selective serotonin reuptake inhibitor is selected from the group consisting of fluoxetine and paroxetine.

29. The method according to claim 22, wherein the norepinephrine serotonin reuptake inhibitor is venlafaxine.

30. The method according to claim 22, wherein the GABA modulator is gabapentin.

31. A composition comprising
(a) at least one compound of Formula I:



wherein:

R^1 is $-(C_1-C_7)$ hydrocarbyl or $-(C_2-C_6)$ heteroalkyl;

R^2 is selected from the group consisting of $-H$, and $-(C_1-C_7)$ hydrocarbyl;

wherein R^1 and R^2 may combine to form a carbocyclic or heterocyclic 5- or 6-membered ring;

R^{3a} , R^{3b} and R^{3c} are independently selected from the group consisting of $-H$, $-O(C_1-C_7)$ hydrocarbyl, $-OH$, $-OC(=O)(C_1-C_6)$ alkyl, $-OC(=O)O(C_1-C_7)$ hydrocarbyl, $-SH$, $-S(C_1-C_3)$ alkyl, $-NH_2$, $-NH(C_1-C_6)$ alkyl, $-N((C_1-C_6)alkyl)_2$, $-NH(=O)(C_1-C_6)$ alkyl, $-NO_2$, and halogen;

provided at least one of R^{3a} , R^{3b} and R^{3c} is other than $-H$;

R^4 and R^5 are independently selected from the group consisting of $-O(C_1-C_7)\text{hydrocarbyl}$, $-OH$, $-OC(=O)(C_1-C_6)\text{alkyl}$, $-OC(=O)O(C_1-C_7)\text{hydrocarbyl}$, $-SH$, $-S(C_1-C_3)\text{alkyl}$, $-NH_2$, $-NH(C_1-C_6)\text{alkyl}$, $-N((C_1-C_6)\text{alkyl})_2$, $-NH(=O)(C_1-C_6)\text{alkyl}$, $-NO_2$, and halogen;

wherein R^4 and R^5 may combine to form a 5-, 6- or 7-membered heterocyclic ring; and

wherein the administered compounds according to Formula I comprise an (*S*)-enantiomer, substantially free of the corresponding (*R*)-enantiomer, with respect to the absolute conformation at the 5-position of the benzodiazepine ring; or

a pharmaceutically-acceptable salt of such a compound; and

(b) at least one additional therapeutic agent selected from the group consisting of estrogen agonists, progesterone agonists, selective estrogen receptor modulators, bisphosphonates; selective serotonin reuptake inhibitors, norepinephrine serotonin reuptake inhibitors and gamma aminobutyric acid modulators.